ECC 2015 | Exploratory analysis of frontline therapies in REVEL: Phase 3 trial of ramucirumab in NSCLC

Giorgio Scagliotti

At the European Cancer Congress (ECC) 2015, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses the exploratory analysis of frontline therapies in REVEL, a randomized phase 3 trial of ramucirumab plus docetaxel versus docetaxel for the treatment of patients with stage IV non-small cell lung cancer (NSCLC) after disease progression on platinum-based therapy.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter